Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Clinical trial NCT05814666 · TERMINATED
Trial details
- NCT number
- NCT05814666
- Sponsor
- Flamingo Therapeutics NV
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-30
- Primary completion
- 2025-08-14
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.